NCT05217238 is a NA clinical trial of Remifentanil in Rocuronium, sponsored by Yangzhou University.

Who is sponsoring NCT05217238?

NCT05217238 is sponsored by Yangzhou University.

What drugs are being tested in NCT05217238?

Interventions in NCT05217238: Remifentanil.

What condition does NCT05217238 study?

NCT05217238 studies Rocuronium, Injection Pain.

Is NCT05217238 still recruiting?

NCT05217238 is currently status unknown. Last updated 1 February 2022.

Last reviewed 2022-02-01 · How we verify

NCT05217238

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Median Effective Dose of Remifentanil for the Prevention of Pain Caused by the Injection of Rocuronium

Status unknown NA Last updated 1 February 2022

What this trial tests

NA trial testing Remifentanil in Rocuronium in 70 participants. Status unknown.

Timeline

18 December 2021

Primary endpoint
30 March 2022

30 March 2022

Quick facts

Lead sponsor	Yangzhou University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	70
Start date	18 December 2021
Primary completion	30 March 2022
Estimated completion	30 March 2022
Sites	1 location across China

Drugs / interventions tested

Remifentanil — full drug profile →

Conditions studied

Rocuronium — all drugs for Rocuronium →
Injection Pain — all drugs for Injection Pain →

Sponsor

Yangzhou University

Who can join

Adults 18 to 80, any sex, with Rocuronium or Injection Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

As a medium-and long-term non-depolarizing muscle relaxant, rocuronium has the advantages of quick effect, no histamine release and accumulation and no obvious cardiovascular adverse reactions, so it has been widely used in clinical anesthesia induction. However, when given intravenously, rocuronium can cause adverse reactions such as injection pain and limb retraction, which can lead to needle prolapse, extravasation of injection drugs, swelling of injection site, serious induction delay, and cardiovascular adverse events in severe cases. Remifentanil is a synthetic opioid drug hydrolyzed by esterase. Compared with other opioid drugs, remifentanil has the advantages of quick effect, short half-life and short time of hemodynamic changes, so it is an ideal analgesic in clinical anesthesia. In this study, in order to provide clinical references, sequential method was used to find the median effective dose (ED50) by means of pre-intravenous injection of Remifentanil to suppress pain in rocuronium injection.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Median Effective Dose of Remifentanil for the Prevention of Pain Caused by the Injection of Rocuronium: An Age-Stratified Study.
Yan S, Wu H, Yu Y, Li N, et al · · 2023 · cited 2× · PMID 36884108 · DOI 10.1007/s40122-023-00490-5

Verify or expand the search:

Other trials of Remifentanil

Trials testing the same drug.

NCT06564857 — Remifentanil Versus Rocuronium for Optimizing Video Laryngoscopy-assisted Tracheal Intubation · Phase 4 · recruiting
NCT07336628 — Propofol vs Remifentanil for Sedation in Gastroscopy · NA · active not recruiting
NCT07301970 — Population Pharmacokinetics of Remifentanil in Low-Weight Critically Ill Patients · recruiting
NCT07092384 — Effect of Remifentanil on Pruritus and Paresthesia of Fospropofol Disodium Anesthesia · NA · completed
NCT06958393 — Effect of Opioid-free Anaesthesia on Postoperative Delirium in Elderly Patients Undergoing Gastrointestinal Surgery · Phase 4 · not yet recruiting

Other recruiting trials for Rocuronium

Currently open trials in the same condition.

NCT06564857 — Remifentanil Versus Rocuronium for Optimizing Video Laryngoscopy-assisted Tracheal Intubation · Phase 4 · recruiting

Other Yangzhou University trials

Trials by the same sponsor.

NCT06517069 — Effect of TEAS Combined With Oxycodone on Postoperative Visceral Pain in Gynecologic Laparoscopic Patients · NA · recruiting
NCT05936918 — Application of Transcutaneous Electrical Acupoint Stimulation in Laparoscopic Cholecystectomy · NA · unknown
NCT05909696 — Median Effective Dose of Rocuronium for the Prevention of Myofibrillation Caused by the Injection of Succinylcholine · NA · completed
NCT05932485 — Effect of Stellate Ganglion Block on New Atrial Fibrillation After Coronary Artery Bypass Grafting · NA · completed
NCT06456710 — Effect of a Psychological Intervention on Stigma: a Randomized Controlled Study · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05217238 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yangzhou University
Last refreshed: 1 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05217238.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing